3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
8
Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Basal Cell
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms by Site
1
Nasopharyngeal Carcinoma
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Melanoma, Cutaneous Malignant
1
Male Urogenital Diseases
1
Locally Advanced Melanoma
1
Female Urogenital Diseases and Pregnancy Complications
1
Female Urogenital Diseases
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Interventions
Oxaliplatin
13
Bevacizumab
11
Capecitabine
10
Fluorouracil
8
Blood Specimen Collection
8
Leucovorin
7
Cetuximab
6
pembrolizumab
5
Folfox protocol
5
trifluridine tipiracil drug combination
4
dostarlimab
4
Nivolumab
4
Irinotecan
4
HMPL-013
4
Drug Therapy
4
fludarabine
3
XELOX
3
Specimen Handling
3
Laparoscopy
3
IFL protocol
3
Cyclophosphamide
3
Biopsy
3
tislelizumab
2
tipiracil
2
regorafenib
2
pertuzumab
2
envafolimab
2
encorafenib
2
cemiplimab
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Colonic Neoplasms
×
relatlimab
×
Clear all
NCT03026140
2026-03-05
NICHE
The Netherlands Cancer Institute
Phase 2
Recruiting
353 enrolled